
Cancer cost US more than $94 billion in lost earnings in 2015
pharmafile | July 4, 2019 | News story | Research and Development | Cancer, economics, health, lost earnings, oncology, pharma
Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer Society.
“The economic burden of lost earnings from premature cancer deaths in the United States appears to be significant,” the American Cancer Society said.
The study estimated that the 492,146 people who died of cancer in 2015 could have lived for a combined total of 8.7 million more years.
If not for cancer, these lost years could have generated billions for the US economy, with Utah losing out on $19.6 million compared $35.3 million for those in Kentucky. In general the loss was biggest in the South and smallest in the West.
The discrepancy can be explained by the high number of smokers and low numbers of people covered by insurance in Southern states.
While 75% of those in Utah with early stage lung cancer went in for treatment, just 50% of those in Louisiana did the same.
Fewer than half of those living in the South had insurance through their employer compared to 60% of those in Utah.
Louis Goss
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe






